Вид документа : Статья из журнала Шифр издания : Автор(ы) : Ryspayeva D. E., Smolanka I. I., Dudnichenko A. S., Lyashenko A. A., Grinevich Yu. A., Gurianov V. G., Koshubarova M. V., Seleznev A. A. Заглавие : Are CD44[[p]]+[[/p]]CD24[[p]]-[[/p]] cells the assumed cancer stem cells in breast cancer? Место публикации : Экспериментальная онкология. - 2017. - Т. 39, № 3. - С. 224-228 (Шифр ЕУ12/2017/39/3) Примечания : Bibliogr. at the end of the art. MeSH-главная: МОЛОЧНОЙ ЖЕЛЕЗЫ НОВООБРАЗОВАНИЯ -- BREAST NEOPLASMS СТВОЛОВЫХ КЛЕТОК ИССЛЕДОВАНИЕ -- STEM CELL RESEARCH ГИСТОЦИТОХИМИЯ -- HISTOCYTOCHEMISTRY АНТИГЕНЫ CD24 -- ANTIGENS, CD24 АНТИГЕНЫ CD44 -- ANTIGENS, CD44 СТАТИСТИЧЕСКАЯ ОБРАБОТКА ДАННЫХ -- DATA INTERPRETATION, STATISTICAL ФОТОГРАФИЧЕСКИЕ СНИМКИ -- PHOTOGRAPHS Ключевые слова (''Своб.индексиров.''): раковые стволовые клетки Аннотация: Identification and characterization of the population of cancer stem cells (CSC) depends on several cellular markers, which combination is specific for the phenotype of CSC in the corresponding tumor. Several markers of CSC have already been identified in breast cancer (BC), but there are no universal indicators that could specifically identify the CSC in BC. Aims: To determine the validation of the CSC model for cell surface markers such as CD44 and CD24 and their clinical significance. Materials and methods: Primary tumor samples of 45 patients with invasive BC without chemotherapy prior to surgery exposure were examined in paraffin blocks. CD44 and CD24 antigens expression was evaluated by the percentage of positive cells using different chromogens and the MultiVision detection system by immunohistochemical method. In this research the evaluation was determined by the following criteria: (-), negative - expression in 10% of tumor cells; (+), positive - expression in ≥10% of cells. The same scoring system was applied for the expression of CD44+/CD24-. Results: 62.2% of investigated patients are patients older than 50 years and most of them with stage II of disease (71.0%) and luminal tumor subtypes (68.9%). We analysed the expression of CD44, CD24 and CD44+/CD24- for diffe-rent patients with dividing them into two groups. The group A consists of patients with unfavorable prognosis (relapses and metastases have occurred in the first three years after diagnosis), and the group B - with a favourable prognosis (the development of metastases after three years). Median disease-free survival in the group A is 19 months, in the group B - 46 months. The difference between the overall survival (OS) curves in the groups A and B is statistically significant (p 0.001), the risk of death was higher in the group A (hazard ratio (HR) 5.9; confidence interval (CI) 2.3-15.2). The content of CD44 cells did not differ statistically between groups A and B (p Доп.точки доступа: Ryspayeva, D. E. Smolanka, I. I. Dudnichenko, A. S. Lyashenko, A. A. Grinevich, Yu. A. Gurianov, V. G. Koshubarova, M. V. Seleznev, A. A.